Myelomatosis

Myelomatosis, or myeloma (from ancient Greek μῦλος - “sweet, tender” + -ωμα - “tumor”) is a malignant tumor of plasma cells of the bone marrow, in which they begin to multiply uncontrollably.

In 1938, German oncologist Walter Heitz first described a malignant tumor that was formed from plasma cells. The tumor was named mylogia (from the Greek myelo - bone marrow). However, this name did not take root, and in 1946, the American doctor Walter Frieden renamed the tumor myeloma. In the 1950s, darling was given a more common name, myeloma, which was accepted throughout the world.
Myeloma is called myeloma if it has spread beyond the bone marrow and metastasized to other organs.

Myelomatosis is a term often used in the medical literature to refer to multiple myeloma. It is a tumor disease of the bone marrow that is characterized by abnormal proliferation of plasma cells in the bone marrow, leading to the formation of tumors.

Myeloma is one of the most common types of bone marrow tumors in adults. It usually occurs in people over 50 years of age, although younger people can also be affected. Myelomatosis can present with a variety of symptoms, including bone pain, fatigue, weakness, increased sensitivity to infection, and anemia.

Approximately 1% of all cancer cases worldwide are myeloma. The disease occurs more often in men than in women. The causes of myelomatosis are not yet fully understood. However, it is believed that genetic factors, environmental conditions and lifestyle may influence the development of this disease.

Various methods are used to diagnose myelomatosis, including blood and urine tests, bone marrow examinations, and x-rays. Treatment for myelomatosis may include chemotherapy, bone marrow transplantation, radiation therapy, and other methods.

Myelomatosis is a serious disease that can lead to various complications, such as a weakened immune system, bone disorders and organ damage. Therefore, it is important to consult a doctor promptly and begin treatment to prevent the development of dangerous complications.

Myelomatic disease appeared in the process of metamorphosis of tumorigenesis, proliferating hematopoietic cells in the bone marrow. An uncontrolled increase in lymphocytes that produce immunoglobulins of an abnormal structure and have altered reactivity leads to the uncontrolled development of the disease. This process can be caused by infectious or chemical development factors, hereditary characteristics of the body. Myeloid disease develops in the following stages: - formation of cells oversaturated with abnormal immunoglobulins; - the appearance of red blood cells in the blood plasma due to increased production of red blood cells;

- weakness of bones and cartilage; disruption of blood cell synthesis;

weakness of internal organs, depression. Symptoms of the myloid form of disease resemble inflammation of the blood plasma, which is associated with a person’s reduced immune status